Improving Biosimilars and Patient Care
Improving Biosimilars and Patient Care
3 PagesImproving Biosimilars and Patient Care Holland & Knight's Public Policy & Regulation (PP&R) Group secured a major victory for pharmaceutical industry client Biosimilars Forum in the Calendar Year (CY) 2018 Medicare Physician Fee Schedule (MPFS) Final Rule. In the Final Rule, which was placed on display at the Federal Register on Nov. 2, the Centers for Medicare & Medicaid Services (CMS) announced a change to its present policy on biosimilar reimbursement. CMS stated that it will begin issuing unique Healthcare Common Procedure Coding System (HCPCS) codes – often referred to as "J-codes" – to each individual biosimilar product. The new codes will start being issued on or after Jan. 1, 2018. The reversal of the existing policy received extensive coverage by the healthcare trade media and is
